To determine whether Medicare covers CAR-T it might soon be important to find out how patients feel.
Pharma sector pushes back against a programme that mandates cheaper prices for hospitals serving the poor.
Biopharma might be getting the pricing controls that it tried to stop.
If investors have visions of Luxturna-like prices they might need to blink and look again.
Medicare Advantage plans have been cleared to seek cheaper alternatives for biologicals beginning next year.
Private price negotiation is a hallmark of the US health care system – banning rebates does not make that any less true.
Novartis is the latest big pharma company to pledge not to increase drug prices. But does this signal a shift in the industry?
A recent US push to end drug rebates might improve transparency, but will do nothing to address the root cause of rising drug costs.
US President Donald Trump’s blueprint offers various proposals to reduce drug prices, some more ambitious than others.